Literature DB >> 33043622

Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.

Yimeng Gao1, Hongzhong Jin1.   

Abstract

Livedoid vasculopathy (LV) is a chronic, recurrent skin disorder with unknown aetiology and pathogenesis that seriously affects the quality of life of people who suffer from it. Plasminogen activator inhibitor (PAI)-1 is a primary inhibitory component of the endogenous fibrinolytic system in blood coagulation. PAI-1 also plays a role in many other physiological processes and activities, including thrombosis, fibrosis, wound healing, angiogenesis, inflammation, cell migration, and adhesion. Enhanced expression and genotype polymorphism of PAI-1 have been observed in LV patients. In this review, we summarise the known functions of PAI-1 with emphasis on the roles that PAI-1 probably plays in the pathogenesis of LV, thereby illustrating that PAI-1 represents a potential LV biomarker and therapeutic target for treating LV.
© 2020 Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd.

Entities:  

Keywords:  aetiology; plasminogen activator inhibitor 1; vascular diseases

Year:  2020        PMID: 33043622      PMCID: PMC7948802          DOI: 10.1111/iwj.13480

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  57 in total

Review 1.  Trauma and thrombosis in the pathogenesis of pressure ulcers.

Authors:  Peter T Lowthian
Journal:  Clin Dermatol       Date:  2005 Jan-Feb       Impact factor: 3.541

2.  Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy.

Authors:  Joana Antunes; Paulo Filipe; Marisa André; Ana Fraga; Gabriel Miltenyi; Manuel Marques Gomes
Journal:  Acta Derm Venereol       Date:  2010       Impact factor: 4.437

3.  Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies.

Authors:  M Papi; B Didona; O De Pità; A Frezzolini; S Di Giulio; W De Matteis; D Del Principe; R Cavalieri
Journal:  Arch Dermatol       Date:  1998-04

4.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.

Authors:  D Ginsburg; R Zeheb; A Y Yang; U M Rafferty; P A Andreasen; L Nielsen; K Dano; R V Lebo; T D Gelehrter
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

5.  Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions.

Authors:  Mehmet Agirbasli; Fatih Göktay; Irem Peker; Pembegul Gunes; Fugen Vardar Aker; Mustafa Akkiprik
Journal:  Cardiovasc Ther       Date:  2017-06       Impact factor: 3.023

6.  Livedoid vasculopathy: clinical features and treatment in 24 Chinese patients.

Authors:  Suiying Feng; Wei Su; Peiying Jin; Changgeng Shao
Journal:  Acta Derm Venereol       Date:  2014-09       Impact factor: 4.437

Review 7.  Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.

Authors:  Florian Schroeck; Nuria Arroyo de Prada; Stefan Sperl; Manfred Schmitt; Magdolen Viktor
Journal:  Biol Chem       Date:  2002 Jul-Aug       Impact factor: 3.915

8.  Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin.

Authors:  M Luo; Y Ji; Y Luo; R Li; W P Fay; J Wu
Journal:  J Thromb Haemost       Date:  2017-11-08       Impact factor: 5.824

Review 9.  Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.

Authors:  James Yarmolinsky; Natália Bordin Barbieri; Tobias Weinmann; Patricia K Ziegelmann; Bruce B Duncan; Maria Inês Schmidt
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

10.  Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.

Authors:  Yimeng Gao; Hongzhong Jin
Journal:  J Dermatolog Treat       Date:  2020-03-09       Impact factor: 3.359

View more
  2 in total

1.  Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.

Authors:  Yimeng Gao; Hongzhong Jin
Journal:  Int Wound J       Date:  2020-10-11       Impact factor: 3.315

2.  Adalimumab in Treating Refractory Livedoid Vasculopathy.

Authors:  Xiao-Wen Huang; Huan-Xin Zheng; Meng-Lei Wang; Wan-Mei He; Mei-Xin Feng; Kang Zeng; Li Li
Journal:  Vaccines (Basel)       Date:  2022-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.